Sinil Pharmaceutical Co., Ltd. (KOSDAQ:012790)

Market Cap	68.49B -6.5%
Revenue (ttm)	80.56B -9.9%
Net Income	7.53B -47.3%
EPS	n/a
Shares Out	11.38M
PE Ratio	9.09
Forward PE	n/a
Dividend	190.00 (3.16%)
Ex-Dividend Date	Dec 29, 2025

Volume	20,265
Average Volume	37,492
Open	6,070.00
Previous Close	6,080.00
Day's Range	5,970.00 - 6,070.00
52-Week Range	5,640.00 - 7,200.00
Beta	0.64
RSI	48.85
Earnings Date	Mar 3, 2026

About Sinil Pharmaceutical

Sinil Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers pharmaceutical products for various indications, such as pain reliever, anti-inflammatory, hyperlipidemia, skin disease, and folic acid deficiency; and general/specialty drugs, veterinary drugs, and OEM products for various diseases. The company also provides cosmetics, including skin care products, etc.; health functional products comprising vitamin supplements; and quasi-drugs for yellow dust, bacteria blocking, etc. In ...

• Industry: Pharmaceutical Preparations
• Founded: 1971
• Employees: 287
• Stock Exchange: KOSDAQ
• Ticker Symbol: 012790

Financial Performance

In 2025, Sinil Pharmaceutical's revenue was 80.56 billion, a decrease of -9.92% compared to the previous year's 89.44 billion. Earnings were 7.53 billion, a decrease of -47.34%.